LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
58.46
-0.84 (-1.42%)
Mar 13, 2026, 4:00 PM EDT - Market closed
LivaNova Revenue
In the year 2025, LivaNova had annual revenue of $1.39B with 10.74% growth. LivaNova had revenue of $360.92M in the quarter ending December 31, 2025, with 13.91% growth.
Revenue (ttm)
$1.39B
Revenue Growth
+8.83%
P/S Ratio
2.30
Revenue / Employee
$420,622
Employees
3,300
Market Cap
3.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.39B | 134.62M | 10.74% |
| Dec 31, 2024 | 1.25B | 99.89M | 8.66% |
| Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
| Dec 31, 2022 | 1.02B | 87.56M | 9.37% |
| Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
| Dec 31, 2019 | 1.08B | 720.93M | 198.47% |
| Dec 31, 2015 | 363.24M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bruker | 3.44B |
| Integer Holdings | 1.85B |
| Haemonetics | 1.32B |
| Inspire Medical Systems | 911.98M |
| Neogen | 880.32M |
| Alphatec Holdings | 764.16M |
| iRhythm Holdings | 747.14M |
| TransMedics Group | 605.49M |
LIVN News
- 13 days ago - Artisan International Small-Mid Fund Q4 2025 Performance Review - Seeking Alpha
- 18 days ago - LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance - Business Wire
- 7 weeks ago - LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results - Business Wire
- 2 months ago - LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - LivaNova to Present at J.P. Morgan Healthcare Conference in January - Business Wire
- 3 months ago - LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting - Business Wire
- 3 months ago - LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea - Business Wire